KTKazuki Tanaka

Kazuki Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kazuki Tanaka has a total of 166 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dynamic chest radiography-derived low-motion area ratio as a potential exploratory quantitative biomarker of idiopathic pleuroparenchymal fibroelastosis

    by Yuya Yamamoto, Shun Matsuura, Kyohei Matsushita, Shoma Matsushita, Taiga Fujita, Kotaro Yamada, Ryuuichi Nakamura, Kyohei Oishi, Kazuki Tanaka, Norimichi Akiyama, et al.

  • Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease

    by Yuzo Suzuki, Katsuhiro Yoshimura, Kazutaka Mori, Masato Kono, Sayomi Matsushima, Shinpei Kato, Kosuke Suzuki, Kazuki Tanaka, Keigo Koda, Toshihiro Masuda, et al.

  • Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study

    by Yohei Kirino, Ayaka Maeda, Kana Higashitani, Nobuyuki Horita, Tomoyuki Asano, Kiyoshi Migita, Yoshikazu Motomura, Ryo Rokutanda, Daisuke Kobayashi, Masao Tamura, et al.


  • Open Access

    MET Exon 14 Skipping Mutation‐Positive Lung Cancer With Multiple Cystic Airspaces: A Case Report

    by Atsuki Asai, Shun Matsuura, Kensuke Kita, Kyohei Matsushita, Ryo Suzuki, Takumi Nagasaki, Yuya Yamamoto, Kotaro Yamada, Ryuuichi Nakamura, Norimichi Akiyama, et al.

    Lung cancer with cystic airspaces (LCCA) is an uncommon radiological presentation that is frequently underrecognised and may be mistaken for benign or infectious pulmonary conditions. We report a case of lung adenocarcinoma presenting with multiple thin‐walled cystic lesions harbouring a MET exon 14 skipping mutation. A 65‐year‐old woman presented with chronic cough and expectoration. Chest imaging revealed multiple cavitary and cystic pulmonary lesions accompanied by mediastinal lymphadenopathy and distant metastases. Endobronchial ultrasound‐guided transbronchial needle aspiration confirmed adenocarcinoma with a MET exon 14 skipping mutation. The patient was diagnosed with Stage IV disease and initiated on tepotinib therapy, resulting in marked regression of the pulmonary lesions. This case underscores the importance of considering malignancy in the differential diagnosis of thin‐walled cystic lung lesions and suggests that MET exon 14‐positive LCCA may represent a distinct molecular subgroup with favourable responsiveness to MET‐targeted therapy.

  • Open Access

    Dynamic Chest Radiography Visualizes Characteristic Respiratory Motion Impairment in Idiopathic Pleuroparenchymal Fibroelastosis: A Case Report

    by Yuya Yamamoto, Shun Matsuura, Kensuke Kita, Kyohei Matsushita, Ryo Suzuki, Takumi Nagasaki, Kotaro Yamada, Ryuichi Nakamura, Kazuki Tanaka, Norimichi Akiyama, et al.

    Idiopathic pleuroparenchymal fibroelastosis (iPPFE) is a rare interstitial lung disease characterized by upper lobe‐predominant pleural fibrosis and restrictive ventilatory impairment. However, methods for functional assessment of respiratory motion remain limited. We reported a 74‐year‐old woman who had severe restrictive impairment secondary to iPPFE, for which dynamic chest radiography (DCR) was used to evaluate respiratory mechanics. Quantitative DCR indices were compared with those of controls without pulmonary disease. DCR demonstrated markedly reduced diaphragmatic excursion, substantial decrease in respiratory lung area changes, and pronounced increase in low‐motion areas, indicating extensive regional motion restriction. These findings were consistent with impaired transmission of diaphragmatic motion due to pleural and subpleural fibrosis. This case illustrated that DCR can visualize and quantify characteristic respiratory motion abnormalities in iPPFE and may serve as a useful complementary modality to high‐resolution computed tomography and pulmonary function testing for functional assessment of iPPFE.


  • Open Access

    Diagnostic Challenge and Treatment Delay in Drowning‐Associated Pneumonia: A Case of Combined Aeromonas , Legionella , and Aspergillus Infection

    by Takafumi Masuda, Kazuki Tanaka, Akira Kawamura, Ryo Suzuki, Takumi Nagasaki, Kotaro Yamada, Ryuuichi Nakamura, Toshiya Hiramatsu, Kana Uchida, Norimichi Akiyama, et al.

    Drowning‐associated pneumonia often involves multiple types of pathogens, including Aeromonas hydrophila, Legionella spp., and fungi. We report the case of an 82‐year‐old man who developed a rare combined infection with these three organisms after freshwater drowning. Initial therapy for typical aspiration pneumonia was ineffective. Although A. hydrophila and Legionella pneumophila were subsequently identified and targeted, the patient’s condition failed to improve. While chest computed tomography on the 11th day of hospitalization revealed worsening infiltrates and new cavity lesions, bronchoscopy was delayed until Day 13 due to circulatory instability. Subsequently, Aspergillus fumigatus was identified from bronchial lavage. Despite starting targeted antimicrobial and antifungal therapy late, the patient died on Day 21. This case highlights that in freshwater drowning, immediate broad‐spectrum empirical treatment covering high‐risk environmental bacteria and Legionella is essential. Furthermore, if initial therapy is ineffective or radiological progression occurs, early bronchoscopy must be performed to identify secondary or opportunistic pathogens, including Aspergillus or other fungi to prevent deadly delays in diagnosis.

  • Open Access

    Immune checkpoint inhibitor‐induced autoimmune limbic encephalitis with positivity for anti‐Hu antibodies in a patient with small‐cell lung cancer: A case report and literature review

    by Lynn Nakahara, Shun Matsuura, Ryo Suzuki, Akira Kawamura, Takumi Nagasaki, Takafumi Masuda, Kotaro Yamada, Ryuuichi Nakamura, Toshiya Hiramatsu, Norimichi Akiyama, et al.

    In recent years, there has been an increasing number of studies on neurological symptoms induced as paraneoplastic neurological syndrome (PNS) or neurological immune‐related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). Herein, we report a 68‐year‐old male patient with small‐cell lung cancer who developed memory impairment and autonomic nervous system dysfunction after three courses of carboplatin, etoposide, and durvalumab therapy. Brain magnetic resonance imaging revealed hyperintense areas restricted to the bilateral temporal lobes. Moreover, based on the blood test results, the patient was strongly positive for anti‐neuronal nuclear antibodies. Hence, he was diagnosed with autoimmune limbic encephalitis (ALE). Corticosteroid pulse therapy was administered. After treatment, the patient exhibited gradual improvement in memory impairment. However, while tapering the prednisolone dose, the patient exhibited relapse of memory disturbance owing to ALE. It is challenging to distinguish PNS from neurological irAEs. However, ICI‐induced ALE with positivity for anti‐Hu antibodies has an extremely poor prognosis.


  • Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry

    by Yohei Kirino, Ayaka Maeda, Tomoyuki Asano, Kiyoshi Migita, Yukiko Hidaka, Hiroaki Ida, Daisuke Kobayashi, Nobuhiro Oda, Ryo Rokutanda, Yuichiro Fujieda, et al.

    We aimed to gather real-world clinical evidence of detailed disease activity, treatments, remission rates, and adverse events (AEs) associated with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome in a prospective study. Patients in Japan suspected of having VEXAS syndrome were enrolled in a registry study. A novel disease activity measure (VEXASCAF) assessing 11 symptoms associated with VEXAS syndrome was evaluated at enrolment and after 3 months. AEs, survival, CRP levels, and treatments were also recorded at enrolment and 3 months after enrolment. All exons of UBA1 were sequenced using a next-generation sequencer to determine the variant allele frequencies of pathogenic variants in the peripheral blood of all patients. Of the 55 registered patients, 30 patients were confirmed to have pathogenic variants of UBA1. All patients were male, with a median age of 73.5 years. VEXASCAF and CRP levels decreased significantly at 3 months post-enrolment, but the oral prednisolone dose did not change. Only two patients achieved complete remission according to FRENVEX at 3 months after enrolment. During the observation period of 6 months, 28 AEs were observed, including 3 deaths, 4 malignancies from two cases, 2 thromboses, and 13 infections (including 4 mycobacterial infections). Inflammation of the lung and cervical region (i.e. parotid and submandibular gland swelling, tonsillitis, cervical swelling, and pain) were the most common AEs. Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications—such as malignancy, thrombosis, and infection—occurred frequently within a short observation period.


  • Open Access

    Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    by Naoki Inui, Takahito Suzuki, Kazuki Tanaka, Masato Karayama, Yusuke Inoue, Kazutaka Mori, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, et al.

    PURPOSE: We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIENTS AND METHODS: Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety. RESULTS: In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, –1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity. CONCLUSION: The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.


  • Open Access

    Development of a novel T cell‐oriented vaccine using CTL/Th‐hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium

    by Kazuki Tanaka, Noriyuki Enomoto, Masahiro Uehara, Kazuki Furuhashi, Shogo Sakurai, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Tomoyuki Fujisawa, et al.

    Antigen‐specific CD8+ T‐lymphocytes (cytotoxic T‐lymphocytes: CTL), as well as CD4+ T‐lymphocytes (helper T‐lymphocytes: Th), simultaneously play an important role in the elimination of intracellular bacteria such as Mycobacterium tuberculosis and Listeria monocytogenes. Administration of T‐cell epitope short peptide needs large numbers of peptides for effective vaccination due to its easily degradable nature in vivo. In this respect, biocompatible and biodegradable microparticles combined with CTL/Th‐hybrid epitope long peptide (long peptide) have been used to diminish the degradation of loaded peptide. The aim of this study is to develop a novel T cell‐oriented vaccine against intracellular bacteria that is composed of long peptide and poly (lactic‐co‐glycolic acid) (PLGA) microparticles. Mouse bone marrow‐derived dendritic cells (BMDCs) were loaded with L. monocytogenes listeriolysin O (LLO)‐derived or ovalbumin (OVA)‐derived long peptide/PLGA or other comparative antigens. The antigen‐loaded BMDCs were injected subcutaneously into the flank of mice twice, and then, the spleens were collected and lymphocyte proliferation and interferon‐γ production were evaluated. The median diameter of the PLGA spheres was 1.38 μm. Both LLO‐ and OVA‐long peptide/PLGA showed significantly more robust CTL and Th proliferations with higher interferon‐γ production than the long peptide alone or CTL and Th short peptides/PLGA vaccination. Furthermore, the LLO‐long peptide/PLGA vaccination showed a significantly lower bacterial burden in spleens compared with the long peptide alone or the CTL and Th short peptides/PLGA vaccination after the challenge of lethal amounts of L. monocytogenes. These results suggest that the novel vaccine taking advantages of CTL/Th‐hybrid epitope long peptide and PLGA microparticle is effective for protection against intracellular bacteria.